Sponsor: SWOG
Sponsor Study ID: S1803
Study Title: Phase III Study of Daratumumab/rHuPH20 (NSC 810307) + Lenalidomide or Lonalidomide as Post Autologous STem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration
CTO #: 103174
NCT Number: NCT04071457
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Multiple Myeloma
Study Objectives: To compare overall survival (OS) between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma (MM) patients. To compare the best overall response rate (ORR), including partial remission (PR), very good partial remission (VGPR), and complete remission (CR, sCR) in the subset of patients not in PR at randomization to lenalidomide versus lenalidomide + daratumumab/rHuPH20 in this patient population.